Analytical tools and approaches for metabolite identification in early drug discovery

Pharmaceutical Research

Volumn 24, Issue 2, 2007, Pages 248-257

  Chen, Yuan ^a   Monshouwer, Mario ^a   Fitch, William L ^a  

^a Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

Identification; Metabolism

Indexed keywords

DRUG METABOLITE;

ANALYTICAL EQUIPMENT; CHEMICAL STRUCTURE; CHROMATOGRAPHY; COMPUTER MODEL; DRUG METABOLISM; ELECTROSPRAY; HYPOTHESIS; IN VITRO STUDY; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET RADIATION;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33846059783     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9162-7     Document Type: Review

References (101)

1. J. L. Walgren, M. D. Mitchell, and D. C. Thompson. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35:325-361 (2005).
2. K. Cox. Special requirements for metabolite characterization. In W. A. Korfmacher (ed)., Using Mass Spectrometry for Drug Metabolism Studies, CRC, Boca Raton, FL, 2005, pp. 229-252.
3. C. E. C. A. Hop. Applications of quadrupole-time-of-flight mass spectrometry to facilitate metabolite identification. Amer. Pharm. Rev. 7:76-79 (2004).
4. G. Hopfgartner and M. Zell. Q Trap MS: a new tool for metabolite identification. In W. A. Korfmacher (ed)., Using Mass Spectrometry for Drug Metabolism Studies, CRC, Boca Raton, FL, 2005, pp. 277-304.
5. D. B. Kassel. High throughput strategies for in vitro ADME assays: how fast we go?. In W. A. Korfmacher (ed)., Using Mass Spectrometry for Drug Metabolism Studies, CRC, Boca Raton, FL, 2005, pp. 83-102.
6. J. Kingston, D. O'Connor, T. Sparey, and S. Thomas. Hyphenated techniques in drug discovery: purity assessment, purification, quantitative analysis and metabolite identification. In J. M. Rosenfeld (ed)., Sample Preparation for Hyphenated Analytical Techniques, CRC, Boca Raton, FL, 2004, pp. 114-149.
7. D. Q. Liu and C. E. C. A. Hop. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. J. Pharm. Biomed. Anal. 37:1-18 (2005).
8. A. E. Nassar and R. E. Talaat. Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov. Today 9:317-327 (2004).
9. A. Nassar, A. Kamel, and C. Clarimont. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov. Today 9:1020-1028 (2004).
10. B. Testa, A. L. Balmat, and A. Long. Predicting drug metabolism: concepts and challenges. Pure Appl. Chem. 76:907-914 (2004).
11. B. Testa, A. L. Balmat, A. Long, and P. Judson. Predicting drug metabolism - an evaluation of the expert system METEOR. Chem. Biodiv. 2:872-885 (2005).
12. S. O. Jonsdottir, F. S. Jorgensen, and S. Brunak. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics 21:2145-2160 (2005).
13. M. R. Anari, R. I. Sanchez, R. Bakhtiar, R. B. Franklin, and T. A. Baillie. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. Anal. Chem. 76:823-832 (2004).
14. M. R. Anari and T. A. Baillie. Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discov. Today 10:711-717 (2005).
15. Y. Borodina, A. Rudik, D. Filimonov, N. Kharchevnikova, A. Dmitriev, V. Blinova, and V. Poroikov. A new statistical approach to predicting aromatic hydroxylation sites. Comparison with model-based approaches. J. Chem. Inf. Comput. Sci. 44:1998-2009 (2004).
16. R. J. Mortishire-Smith, D. O'Connor, J. M. Castro-Perez, and J. Kirby. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun. Mass Spectrom. 19:2659-2670 (2005).
17. A. Tevell, U. Bondesson, K. Toerneke, and M. Hedeland. Identification of some new clemastine metabolites in dog, horse, and human urine with liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 18:2267-2272 (2004).
18. G. Cruciani, E. Carosati, B. De, Boeck, K. Ethirajulu, C. Mackie, T. Howe, and R. Vianello. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 48:6970-6979 (2005).
19. M. Y. Lee, C. B. Park, J. S. Dordick, and D. S. Clark. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc. Natl. Acad. Sci. U. S. A. 102:983-987 (2005).
20. O. Pelkonen, M. Turpeinen, J. Uusitalo, A. Rautio, and H. Raunio. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 96:167-175 (2005).
21. D. C. Ackley, K. T. RockichT. R. Baker. Metabolic stability assessed by liver microsomes and hepatocytes. In Z. Yan and G. W. Caldwell (eds.), Optimization Drug Discovery, Humana, Totowa, New Jersey, 2004, pp. 151-162.
22. E. Kantharaj, P. B. Ehmer, A. Tuytelaars, A. Van, Vlaslaer, C. Mackie, and R. A. H. J. Gilissen. Simultaneous measurement of metabolic stability and metabolite identification of 7-methoxymethylthiazolo [3,2-a]pyrimidin-5-one derivatives in human liver microsomes using liquid chromatography/ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 19:1069-1074 (2005).
23. A. C. Li, D. Alton, M. S. Bryant, and W. Z. Shou. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun. Mass Spectrom. 19:1943-1950 (2005).
24. B. V. Karanam, C. E. C. A. Hop, D. Q. Liu, M. Wallace, D. Dean, H. Satoh, M. Komuro, K. Awano, and S. H. Vincent. In vitro metabolism of MK-0767 [(+-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor a/g agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases. Drug Metab. Dispos. 32:1015-1022 (2004).
25. Z. Miao, A. Kamel, and C. Prakash. Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metab. Dispos. 33:879-883 (2005).
26. M. J. Gomez-Lechon, M. T. Donato, J. V. Castell, and R. Jover. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5:443-462 (2004).
27. C. A. Evans, H. E. Fries, and K. W. Ward. In vitro metabolic fate of a novel structural class: evidence for the formation of a reactive intermediate on a benzothiophene moiety. Chem. Biol. Interact. 152:25-36 (2005).
28. R. Gebhardt, J. G. Hengstler, D. Mueller, R. Gloeckner, P. Buenning, B. Laube, E. Schmelzer, M. Ullrich, D. Utesch, N. Hewitt, M. Ringel, B. R. Hilz, A. Bader, A. Langsch, T. Koose, H. J. Burger, J. Maas, and F. Oesch. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 35:145-213 (2003).
29. J. C. Zguris, L. J. Itle, D. Hayes, and M. V. Pishko. Microreactor microfluidic systems with human microsomes and hepatocytes for use in metabolite studies. Biomed. Microdev. 7:117-125 (2005).
30. L. Vignati, E. Turlizzi, S. Monaci, P. Grossi, R. Kanterde, and M. Monshouwer. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167 (2005).
31. E. F. A. Brandon, T. M. Bosch, M. J. Deenen, R. Levink, E. van der, Wal, J. B. M. van, Meerveld, M. Bijl, J. H. Beijnen, J. H. M. Schellens, and I. Meijerman. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, Phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. Toxicol. Appl. Pharmacol. 211:1-10 (2006).
32. R. A. Kemper and D. L. Nabb. In vitro studies in microsomes from rat and human liver, kidney, and intestine suggest that perfluorooctanoic acid is not a substrate for microsomal UDP-glucuronosyltransferases. Drug Chem. Toxicol. 28:281-287 (2005).
33. B. Blankert, H. Hayen, S. M. van, Leeuwen, U. Karst, E. Bodoki, S. Lotrean, R. Sandulescu, N. M. Diez, O. Dominguez, J. Arcos, and J. M. Kauffmann. Electrochemical, chemical and enzymatic oxidations of phenothiazines. Electroanalysis 17:1501-1510 (2005).
34. I. Beattie, K. Joncour, and K. Lawson. Ultra performance liquid chromatography coupled to orthogonal quadrupole TOF-MS(MS) for metabolite identification. LC-GC Europe 24:19-21 (2005).
35. J. Castro-Perez, R. Plumb, J. H. Granger, I. Beattie, K. Joncour, and A. Wright. Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 19:843-848 (2005).
36. M. I. Churchwell, N. C. Twaddle, L. R. Meeker, and D. R. Doerge. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatog. B 825:134-143 (2005).
37. C. Giroud, K. Michaud, F. Sporkert, C. Eap, M. Augsburger, P. Cardinal, and P. Mangin. A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry (HILIC-MS). J. Anal. Toxicol. 28:464-474 (2004).
38. A. Baldacci, J. Caslavska, A. B. Wey, and W. Thormann. Identification of new oxycodone metabolites in human urine by capillary electrophoresis-multiple- stage ion-trap mass spectrometry. J. Chromatogr. A 1051:273-282 (2004).
39. F. Peters, M. Meyer, G. Fritschi, and H. Maurer. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone MPBP in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B 824:81-91 (2005).
40. A. Ewald, F. Peters, M. Weise, and H. Maurer. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine 4-MTA in human urine using gas chromatography-mass spectrometry. J. Chromatogr. B 824:123-131 (2005).
41. W. L. Fitch, M. McGregor, A. R. Katritzky, A. Lomaka, R. Petrukhin, and M. Karelson. Prediction of ultraviolet spectral absorbance using quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 42:830-840 (2002).
42. Y. Cai, D. Kingery, O. McConnell, and A. C. Bach II. Advantages of atmospheric pressure photoionization mass spectrometry in support of drug discovery. Rapid Commun. Mass Spectrom. 19:1717-1724 (2005).
43. S. Ma, S. K. Chowdhury, and K. B. Alton. Thermally induced N-to-O rearrangement of tert-N-Oxides in atmospheric pressure chemical ionization and atmospheric pressure photoionization mass spectrometry: differentiation of N-Oxidation from hydroxylation and potential determination of N-Oxidation site. Anal. Chem. 77:3676-3682 (2005).
44. W. L. Fitch, P. W. Berry, Y. Tu, A. Tabatabaei, L. Lowrie, F. Lopez-Tapia, Y. Liu, D. Nitzan, M. R. Masjedizadeh, and A. Varadarajan. Identification of glutathione-derived metabolites from an IP receptor antagonist. Drug Metab. Dispos. 32:1482-1490 (2004).
45. J. Olsen, C. Li, I. Bjornsdottir, U. Sidenius, S. H. Hansen, and L. Z. Benet. In vitro and in vivo studies on acyl-coenzyme Adependent bioactivation of zomepirac in rats. Chem. Res. Toxicol. 18:1729-1736 (2005).
46. P. H. Stahl and C. G. Wermuth (eds.). Handbook of Pharmaceutical Salts: Properties, Selection and Use, Wiley VCH, Zurich, 2002, pp. 25.
47. D. Q. Liu, B. V. Karanam, G. A. Doss, R. R. Sidler, S. H. Vincent, and C. E. C. A. Hop. In vitro metabolism of MK-0767 [(+-)-5-[(2,4- dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a peroxisome proliferator-activated receptor a/g agonist. II. Identification of metabolites by liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 32:1023-1031 (2004).
48. P. Eichhorn, P. L. Ferguson, S. Perez, and D. S. Aga. Application of ion Trap-MS with H/D exchange and QqTOF-MS in the identification of microbial degradates of trimethoprim in nitrifying activated sludge. Anal. Chem. 77:4176-4184 (2005).
49. L. Zhou, D. R. Thakker, R. D. Voyksner, M. Anbazhagan, D. W. Boykin, J. E. Hall, and R. R. Tidwell. Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 39:351-360 (2004).
50. G. Hopfgartner, E. Varesio, V. Tschaeppaet, C. Grivet, E. Bourgogne, and L. A. Leuthold. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J. Mass Spectrom. 39:845-855 (2004).
51. T. Mauriala, N. Chauret, R. Oballa, D. A. Nicoll-Griffith, and K. P. Bateman. A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry. Rapid Commun. Mass Spectrom. 19:1984-1992 (2005).
52. J. P. Qiao, Z. Abliz, F. M. Chu, P. L. Hou, F. Liang, Y. Chang, and Z. R. Guo. Application of a novel quadrupole linear ion trap mass spectrometer to study the metabolism of 6-aminobutylphthalide in rat brains. Rapid Commun. Mass Spectrom. 18:3142-3147 (2004).
53. M. Wrona, T. Mauriala, K. P. Bateman, R. J. Mortishire-Smith, and D. O'Connor. 'All-in-One' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun. Mass Spectrom. 19:2597-2602 (2005).
54. L. Leclercq, C. Delatour, I. Hoes, F. Brunelle, X. Labrique, and J. Castro-Perez. Use of a five-channel multiplexed electrospray quadrupole time-of-flight hybrid mass spectrometer for metabolite identification. Rapid Commun. Mass Spectrom. 19:1611-1618 (2005).
55. A.-E. F. Nassar, Y. Parmentier, M. Martinet, and D. Y. Lee. Liquid chromatography-accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies. J. Chromatogr. Sci. 42:348-353 (2004).
56. D. J. Foltz, J. Castro-Perez, P. Riley, J. R. Entwisle, and T. R. Baker. Narrow-bore sample trapping and chromatography combined with quadrupole/time-of-flight mass spectrometry for ultra-sensitive identification of in vivo and in vitro metabolites. J. Chromatogr. B 825:144-151 (2005).
57. R. F. Staack, E. Varesio, and G. Hopfgartner. The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites. Rapid Commun. Mass Spectrom. 19:618-626 (2005).
58. L. Zhang, J. D. Laycock, and K. J. Miller. Quantitative small molecule bioanalysis using chip-based nanoESI-MS/MS. J. Assoc. Lab. Automat. 9:109-114 (2004).
59. H. Idborg, P. Edlund, and S. Jacobsson. Multivariate approaches for efficient detection of potential metabolites from liquid chromatography/mass spectrometry data. Rapid Commun. Mass Spectrom. 18:944-954 (2004).
60. C. A. Smith, E. J. Want, G. O'Maille, R. Abagyan, and G. Siuzdak. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78:779-787 (2006).
61. A.-E. F. Nassar and P. E. Adams. Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction. Curr. Drug Metab. 4:259-271 (2003).
62. W. Windig, W. F. Smith, and W. F. Nichols. Fast interpretation of complex LC/MS data using chemometrics. Anal. Chim. Acta 446:467-476 (2001).
63. G. Zurek, W. D. Herzog, A. Germanus, O. Raether, V. Krone, A. Ingendoh, and C. Baessmann. Rapid metabolite identification using accurate and MSn mass spectra in combination with smart processing tools. In The Applications Book, LC-GC Europe, Chester, UK, 2004, pp. 24-25.
64. Z. Yan, N. Maher, R. Torres, G. Caldwell, and N. Huebert. Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19:3322-3330 (2005).
65. A. Deroussent, M. Re, H. Hoellinger, E. Vanquelef, O. Duval, M. Sonnier, and T. Cresteil. In vitro metabolism of ethoxidine by human CYP1A1 and rat microsomes: identification of metabolites by high-performance liquid chromatography combined with electrospray tandem mass spectrometry and accurate mass measurements by time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 18:474-482 (2004).
66. T. Pfeifer, J. Tuerk, and R. Fuchs. Structural characterization of sulfadiazine metabolites using H/D exchange combined with various MS/MS experiments. J. Am. Soc. Mass Spectrom. 16:1687-1694 (2005).
67. M. L. Bandu, K. R. Watkins, M. L. Bretthauer, C. A. Moore, and H. Desaire. Prediction of MS/MS Data. 1. a focus on pharmaceuticals containing carboxylic acids. Anal. Chem. 76:1746-1753 (2004).
68. L. Yi, M. L. Bandu, and H. Desaire. Identifying lactone hydrolysis in pharmaceuticals. A tool for metabolite structural characterization. Anal. Chem. 77:6655-6663 (2005).
69. S. Tachibana, M. Tanaka, Y. Fujimaki, W. Suzuki, T. Ookuma, Y. Ohori, K. I. Hayashi, H. Iwata, O. Okazaki, and K. I. Sudo. Metabolism of the calmodulin antagonist DY-9760e in animals and humans. Xenobiotica 35:499-517 (2005).
70. M. Sandvoss, A. D. Roberts, I. M. Ismail, and S. E. North. Direct on-line hyphenation of capillary liquid chromatography to nuclear magnetic resonance spectroscopy: practical aspects and application to drug metabolite identification. J. Chromatogr. A 1028:259-266 (2004).
71. M. Sandvoss, B. Bardsley, T. L. Beck, E. Lee-Smith, S. E. North, P. J. Moore, A. J. Edwards, and R. J. Smith. HPLC-SPE-NMR in pharmaceutical development: capabilities and applications. Magn. Reson. Chem. 43:762-770 (2005).
72. M. Godejohann, L. H. Tseng, U. Braumann, J. Fuchser, and M. Spraul. Characterization of a paracetamol metabolite using online LC-SPE-NMR-MS and a cryogenic NMR probe. J. Chromatogr. A 1058:191-196 (2004).
73. I. M. Ismail, P. D. Andrew, J. Cholerton, A. D. Roberts, G. J. Dear, S. Taylor, K. M. Koch, and D. A. Saynor. Characterization of the metabolites of alosetron in experimental animals and human. Xenobiotica 35:131-154 (2005).
74. K. Sohda, T. Minematsu, T. Hashimoto, K. Suzumura, M. Funatsu, K. Suzuki, H. Imai, T. Usui, and H. Kamimura. Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate YM872. Chem. Pharm. Bull. 52:1322-1325 (2004).
75. G. Grosa, U. Galli, B. Rolando, R. Fruttero, G. Gervasio, and A. Gasco. Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan. Xenobiotica 34:345-352 (2004).
76. R. Martino, V. Gilard, F. Desmoulin, and M. Malet-Martino. Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. J. Pharm. Biomed. Anal. 38:871-891 (2005).
77. H. Orhan, J. N. M. Commandeur, G. Sahin, U. Aypar, A. Sahin, and N. P. E. Vermeulen. Use of 19F-nuclear magnetic resonance and gas chromatography- electron capture detection in the quantitative analysis of fluorine-containing metabolites in urine of sevoflurane-anaesthetized patients. Xenobiotica 34:301-316 (2004).
78. E. Skordi, I. D. Wilson, J. C. Lindon, and J. K. Nicholson. Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism. Xenobiotica 34:1075-1089 (2004).
79. C. E. C. A. Hop, Y. Chen, and L. J. Yu. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun. Mass Spectrom. 19:3139-3142 (2005).
80. D. C. Liebler and F. P. Guengerich. Elucidating mechanisms of drug-induced toxicity. Nature Rev. Drug Disc. 4:410-420 (2005).
81. A. S. Kalgutkar and J. R. Soglia. Minimising the potential for metabolic activation in drug discovery. Exp. Opin. Drug. Metab. 1:91-142 (2005).
82. A. S. Kalgutkar, I. Gardner, R. S. Obach, C. L. Shaffer, E. Callegari, K. R. Henne, A. E. Mutlib, D. K. Dalvie, J. S. Lee, Y. Nakai, J. P. O'Donnell, J. Boer, and S. P. Harriman. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6:161-225 (2005).
83. B. R. Baer, A. E. Rettie, and K. R. Henne. Bioactivation of 4-Ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem. Res. Toxicol. 18:855-864 (2005).
84. J. Castro-Perez, R. Plumb, L. Liang, and E. Yang. A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun. Mass Spectrom. 19:798-804 (2005).
85. K. Johnson and R. Plumb. Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J. Pharm. Biomed. Anal. 39:805-810 (2005).
86. C. M. Dieckhaus, C. L. Fernandez-Metzler, R. King, P. H. Krolikowski, and T. A. Baillie. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol. 18:630-638 (2005).
87. R. S. John, P. H. Shawn, Z. Sabrina, B. John, J. C. Mark, G. B. James, and G. C. Leonard. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro- electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 36:105-116 (2004).
88. Z. Yan and G. W. Caldwell. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal. Chem. 76:6835-6847 (2004).
89. T. M. Baughman, R. A. Graham, K. Wells-Knecht, I. S. Silver, L. O. Tyler, M. Wells-Knecht, and Z. Zhao. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. 33:733-738 (2005).
90. Z. Yan, J. Li, N. Huebert, G. W. Caldwell, Y. Du, and H. Zhong. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab. Dispos. 33:706-713 (2005).
91. D. Argoti, L. Liang, A. Conteh, L. Chen, D. Bershas, C. P. Yu, P. Vouros, and E. Yang. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol. 18:1537-1544 (2005).
92. S. Bolze. In vitro screening assay of the reactivity of acyl glucuronides. In Z. YanG. W. Caldwell (eds.), Optimization Drug Discovery, Humana, Totowa, New Jersey, 2004, pp. 385-404.
93. J. Q. Dong, J. Liu, and P. C. Smith. Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. Biochem. Pharmacol. 70:937-948 (2005).
94. A. G. Siraki, T. Chevaldina, and P. J. O'Brien. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem. Biol. Interact. 151:177-191 (2005).
95. S. J. Vanderhoeven, J. Troke, G. E. Tranter, I. D. Wilson, J. K. Nicholson, and J. C. Lindon. Nuclear magnetic resonance (NMR) and quantitative structure-activity relationship (QSAR) studies on the transacylation reactivity of model 1b-O-acyl glucuronides. II: QSAR modeling of the reaction using both computational and experimental NMR parameters. Xenobiotica 34:889-900 (2004).
96. S. Wainhaus. Acyl glucuronides: assays and issues. In W. A. Korfmacher (ed)., Using Mass Spectrometry for Drug Metabolism Studies, CRC, Boca Raton, FL, 2005, pp. 175-202.
97. J. Wang, M. Davis, F. Li, F. Azam, J. Scatina, and R. Talaat. A novel approach for predicting acyl glucuronide reactivity via Schiff Base Formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem. Res. Toxicol. 17:1206-1216 (2004).
98. S. H. Day, A. Mao, R. White, T. Schulz-Utermoehl, R. Miller, and M. G. Beconi. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 52:278-285 (2005).
99. J. Gan, T. W. Harper, M. M. Hsueh, Q. Qu, and W. G. Humphreys. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18:896-903 (2005).
100. J. Gan. Fluorescently labeled thiol-containing trapping agent for the quantitation and identification of reactive metabolites in vitro. (USA). 2005-31292[2005186651], 6-20050825. US. 1-7-2005. Ref Type: Patent.
101. S. Miao, J. Ma, and R. Cho. Formation of NADP+ adducts as a amajor rat/human hepatic microsomal pathway for a novel class of IKKb inhibitors containing thienopyridine. Drug Metab. Rev. 37:155 (2005).